Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab and Radiotherapy in NSCLC
NCT00369447Phase 2Terminated
- Sponsor
- YM BioSciences
- Start
- Mar 2009
- Primary completion
- Jun 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Nimotuzumab + Radiotherapy with Placebo + Radiotherapy (2 arms). Primary endpoints: Overall Survival and Biologically Effective Dose at 2.5 years. Started Mar 2009; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00369447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369447.